xeljanz 5mg tablets
pfizer ltd - tofacitinib citrate - tablet - 5mg
xeljanz tablet 5mg
pfizer private limited - tofacitinib citrate - tablet, film coated - 8.078mg - tofacitinib citrate 8.078mg
xeljanz
pfizer europe ma eeig - tofacitinib - arthritis, rheumatoid - immunosuppressants - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5.1). tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4.4 and 4.5).psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5.1).ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards).tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
tofacitinib 5mg tablets
special order - tofacitinib citrate - oral tablet - 5mg
xeljanz 10mg tablets
pfizer ltd - tofacitinib citrate - tablet - 10mg
xeljanz 5 mg
pfizer pharmaceuticals israel ltd - tofacitinib - tablets - tofacitinib 5 mg - tofacitinib - rheumatoid arthritis tofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards). tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate. psoriatic arthritis tofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy. ulcerative colitis tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent ankylosing spondylitis tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapyjuvenile idiopathic arthritis (jia) tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.
xeljanz 5 mg
pfizer pharmaceuticals israel ltd - tofacitinib - tablets - tofacitinib 5 mg - tofacitinib - rheumatoid arthritis tofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards). tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate. psoriatic arthritis tofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy. ulcerative colitis tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent ankylosing spondylitis tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapyjuvenile idiopathic arthritis (jia) tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.
xeljanz 5 mg film-coated tablet film-coated tablet
pfizer, united states - tofacitinib - film-coated tablet - 5 mg
xeljanz xr 11 mg extended release tablet modified-release tablet
pfizer, united states - tofacitinib - modified-release tablet - 11 mg
trijan 10mg tablets 10 mg
شركة أدوية الحكمة - hikma pharmaceuticals - tofacitinib 10 mg - 10 mg